



Announcement Summary

Entity name

BLINKLAB LIMITED

Date of this announcement

Friday February 13, 2026

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	Performance Rights - FDA Approval	1,400,000	12/02/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

BLINKLAB LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

652901703

1.3 ASX issuer code

BB1

1.4 The announcement is

New announcement

1.5 Date of this announcement

13/2/2026



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class)

ASX +security code

New class - code to be confirmed

+Security description

Performance Rights - FDA Approval

+Security type

Other

ISIN code**Date the +securities the subject of this notification were issued**

12/2/2026

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://announcements.asx.com.au/asxpdf/20241004/pdf/068rn80z6q9ljg.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification**Issue details**

Number of +securities

1,400,000



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
BB1 : ORDINARY FULLY PAID	87,994,487

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
BB1AF : PERFORMANCE RIGHTS RESTRICTED	3,000,000
BB1AE : OPTION EXPIRING 02-APR-2029 RESTRICTED	2,000,000
BB1AD : OPTION EXPIRING 17-SEP-2026 RESTRICTED	33,000,000
BB1AC : ORDINARY FULLY PAID RESTRICTED	37,913,846
BB1AG : OPTION EXPIRING 17-SEP-2026 EX \$0.25	525,000
BB1AH : OPTION EXPIRING 27-SEP-2029 EX \$0.35	1,750,000
BB1AJ : OPTION EXPIRING 27-SEP-2029 EX \$0.35 24M VESTING	1,000,000
BB1AK : OPTION EXPIRING 09-JUL-2028 EX \$0.45	6,023,333
New class - code to be confirmed : Performance Rights - FDA Approval	1,400,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

13